Clinical Trial Update: Safety and Efficacy Study of Gene Therapy Drug (Neovasculgen) to Treat Secondary Raynaud's Phenomenon [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial to evaluate the safety and efficacy of Neovasculgen for secondary Raynaud's phenomenon; the status is unknown based on the trial entry.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Raynaud Phenomenon

Drugs mentioned

• Neovasculgen (VEGF165 plasmid DNA (pl-VEGF165))

Snippet

Sponsor: Artgen Biotech | Conditions: Secondary Raynaud's Phenomenon | Phase 1, Phase 2 | Status: UNKNOWN